Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms ...

One patient assigned to ibrutinib-venetoclax developed myelodysplastic syndrome / acute myeloid leukemia (AML), as did eight patients assigned to FCR.

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

And I think we'll get into, you know, the probably greatest unmet need is, once we do fail HMA-based therapy, particularly for higher risk myelodysplastic syndrome patients, there's really nothing.

Source Reference: Bataller A, et al "Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre ...

First-line therapy was hypomethylating agent (HMA) monotherapy, lenalidomide, and venetoclax (20, 2, and 2 percent, respectively); the remaining patients were treated with supportive care.

Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies Abstract #: 6505 Format: Oral Presentation ...